# reload+after+2024-01-22 16:43:45.621832
address1§4710 Bellaire Boulevard
address2§Suite 210
city§Bellaire
state§TX
zip§77401
country§United States
phone§832 742 1357
website§https://www.biopathholdings.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
fullTimeEmployees§10
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Peter H. Nielsen MBA', 'age': 74, 'title': 'Co-Founder, Chairman of the Board, CEO, President, CFO & Treasurer', 'yearBorn': 1949, 'fiscalYear': 2022, 'totalPay': 722678, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Douglas P. Morris', 'age': 67, 'title': 'Co-Founder, Director of Investor Relations, Secretary & Director', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 110681, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael  Hickey M.B.A.', 'title': 'VP of Clinical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Anthony  Price', 'title': 'Senior Vice President of Finance, Accounting & Administration', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Ana Tari Ashizawa Ph.D., MBA', 'title': 'Senior Vice President of Research, Development & Clinical Design', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.562
currency§USD
dateShortInterest§1702598400
forwardEps§-1.04
exchange§NCM
quoteType§EQUITY
shortName§Bio-Path Holdings, Inc.
longName§Bio-Path Holdings, Inc.
firstTradeDateEpochUtc§1204641000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§487c045c-5873-31de-8241-9c7b0f1dc686
gmtOffSetMilliseconds§-18000000
targetHighPrice§12.0
targetLowPrice§12.0
targetMeanPrice§12.0
targetMedianPrice§12.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§1
quickRatio§1.733
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
